AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18210737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 10929769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel exposure (10 ppm for 1 week, then 100 ppm for 1 week)
Number of subjects: 65
Study 10929769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel exposure
Number of subjects: 65
Study 10929769 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle exposure)
Number of subjects: 65
Study 8819058 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic knee bandage
Number of subjects: 39
Study 8819058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 8819058 — intervention group
Group type: COMPARATOR
Intervention: Patients with patella dislocation (no intervention)
Number of subjects: 39
Study 1478287 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal blunt esophagectomy (THE)
Number of subjects: 86
Study 1478287 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic-abdominal esophagectomy (TTE)
Number of subjects: 86
Study 1478287 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (THE and TTE)
Number of subjects: 86
Study 6143336 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 51
Study 6143336 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 51
Study 6143336 — intervention group
Group type: COMPARATOR
Intervention: Medicated subjects (14)
Number of subjects: 51
Study 6143336 — intervention group
Group type: EXPERIMENTAL
Intervention: Task performance (accuracy in stimulus counting)
Number of subjects: 51
Study 31664343 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR rehabilitation (60 minutes, 18 sessions, three days per week for six weeks)
Number of subjects: 65
Study 31664343 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (45 minutes) and sham VR program (15 minutes)
Number of subjects: 65
Study 29318861 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat Sensitive Moxibustion (HSM)
Number of subjects: 70
Study 29318861 — intervention group
Group type: COMPARATOR
Intervention: Manual Acupuncture
Number of subjects: 70
Study 25964246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 501
Study 25964246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus radiotherapy (RT)
Number of subjects: 501
Study 25964246 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal A subtype
Number of subjects: 501
Study 25964246 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal B subtype
Number of subjects: 501
Study 25964246 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk subtypes
Number of subjects: 501
Study 25964246 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical low-risk luminal A tumors (n = 151)
Number of subjects: 501
Study 25964246 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk cohort (n = 341)
Number of subjects: 501
Study 25964246 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 501
Study 25964246 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk group
Number of subjects: 501
Study 23835207 — intervention group
Group type: EXPERIMENTAL
Intervention: Governmentally-led physical activity program (Youp'là Bouge) implemented in 58 child care centers, including training of educators, adaptation of the built environment, parental involvement, and daily physical activity from September 2009 to June 2010.
Number of subjects: 648
Study 23835207 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=201)
Number of subjects: 648
Study 21911665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin, 0.3%
Number of subjects: 24
Study 21911665 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 1%
Number of subjects: 24
Study 21911665 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin, 0.3%
Number of subjects: 24
Study 21911665 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin hydrochloride, 0.5%
Number of subjects: 24
Study 21911665 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated fellow eye)
Number of subjects: 24
Study 21911665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treated eyes
Number of subjects: 24
Study 19249176 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 0
Study 19249176 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study 16905817 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 112
Study 15269581 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel dressing
Number of subjects: 23
Study 15269581 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze dressing
Number of subjects: 23
Study 11708243 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Elaboration (NE) intervention using generic visual cue cards
Number of subjects: 99
Study 11708243 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NE intervention)
Number of subjects: 99
Study 11708243 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Elaboration (NE) intervention
Number of subjects: 99
Study 11708243 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-SES preschoolers
Number of subjects: 99
Study 9659302 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing sessions (10 weekly sessions)
Number of subjects: 57
Study 9659302 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 57
Study 7654646 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry
Number of subjects: 43
Study 7654646 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry (assuming correct results)
Number of subjects: 43
Study 2569062 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of CVP when supine before fluid replacement
Number of subjects: 16
Study 2569062 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of CVP when sat at 45 degrees before fluid replacement
Number of subjects: 16
Study 2569062 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of CVP when supine after fluid replacement
Number of subjects: 16
Study 2569062 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of CVP when sat at 45 degrees after fluid replacement
Number of subjects: 16
Study 12713 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (40 mg)
Number of subjects: 17
Study 12713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31219254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 20
Study 31219254 — intervention group
Group type: COMPARATOR
Intervention: Static Rest (SR)
Number of subjects: 20
Study 28971875 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg QD) + Sofosbuvir (400 mg QD) + Ledipasvir (90 mg QD)
Number of subjects: 40
Study 28971875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg QD) + Sofosbuvir (400 mg QD)
Number of subjects: 40
Study 28971875 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir-sofosbuvir-ledipasvir regimen
Number of subjects: 40
Study 25590761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (BF)
Number of subjects: 73
Study 25590761 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Unilateral ECT (RUL)
Number of subjects: 73
Study 25590761 — intervention group
Group type: COMPARATOR
Intervention: Both BF and RUL ECT
Number of subjects: 73
Study 23585901 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (90 min/day, 2 days/week, for 6 months)
Number of subjects: 100
Study 23585901 — intervention group
Group type: COMPARATOR
Intervention: Education control group (attended two education classes)
Number of subjects: 100
Study 22253488 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 34
Study 22253488 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-guided PRK
Number of subjects: 34
Study 19433558 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole administered via nasogastric tube (400 mg)
Number of subjects: 0
Study 19433558 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole administered orally (400 mg)
Number of subjects: 0
Study 19433558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both administration routes (oral and nasogastric tube)
Number of subjects: 0
Study 16491580 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg x kg(‐1) x d(‐1) caffeine (G3)
Number of subjects: 59
Study 16491580 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg x kg(‐1) x d(‐1) caffeine (G6)
Number of subjects: 59
Study 16491580 — intervention group
Group type: COMPARATOR
Intervention: 0 mg x kg(‐1) x d(‐1) caffeine (G0)
Number of subjects: 59
Study 12574202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (3.3 microg/kg)
Number of subjects: 8
Study 12574202 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 10325289 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 600 mg daily for 3 months
Number of subjects: 77
Study 10325289 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 77
Study 10325289 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 77
Study 8576674 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened physician-nurse collaboration
Number of subjects: 0
Study 8576674 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team approach
Number of subjects: 0
Study 2016152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 223
Study 2016152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 223
Study 2016152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 223
Study 2016152 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 223
Study 7472106 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-containing infusates
Number of subjects: 49
Study 7472106 — intervention group
Group type: COMPARATOR
Intervention: Standard infusates (Control)
Number of subjects: 49
Study 7472106 — intervention group
Group type: COMPARATOR
Intervention: Control group (Standard infusates)
Number of subjects: 49
Study 7472106 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin group
Number of subjects: 49
Study 7472106 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized fluids
Number of subjects: 49
Study 4038553 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (2-week tapering dose from 0.15 mg/kg/d)
Number of subjects: 49
Study 4038553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 28950422 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 5908
Study 28950422 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (placebo or orlistat)
Number of subjects: 5908
Study 25851331 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based e-learning (14 short screencasts, each 5 minutes, plus a 60-minute on-site discussion)
Number of subjects: 62
Study 25851331 — intervention group
Group type: COMPARATOR
Intervention: Classroom-based presentations
Number of subjects: 62
Study 25851331 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective structured clinical exam
Number of subjects: 62
Study 25851331 — intervention group
Group type: EXPERIMENTAL
Intervention: Test B (MC test directly after HT)
Number of subjects: 62
Study 25851331 — intervention group
Group type: EXPERIMENTAL
Intervention: Test C (MC test 1 day after the course)
Number of subjects: 62
Study 25332476 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated fatty acids (UNSAT) meal
Number of subjects: 21
Study 25332476 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA) meal
Number of subjects: 21
Study 22613271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular cholecalciferol (600,000 IU)
Number of subjects: 116
Study 22613271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (600,000 IU)
Number of subjects: 116
Study 20411443 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet self-management program
Number of subjects: 2603
Study 20411443 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive volunteers vs. telephone respondents
Number of subjects: 2603
Study 17506591 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril (5 mg/day to 20 mg/day)
Number of subjects: 112
Study 17506591 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil (4 mg/day to 16 mg/day)
Number of subjects: 112
Study 17506591 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 112
Study 17506591 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil
Number of subjects: 112
Study 17506591 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 112
Study 15956037 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 cycles of CMF chemotherapy
Number of subjects: 1241
Study 15956037 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of CMF chemotherapy
Number of subjects: 1241
Study 15956037 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1241
Study 12419084 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day and medroxyprogesterone acetate (MPA) 5 mg/day
Number of subjects: 50
Study 12419084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 50
Study 10331686 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak tibial lead levels
Number of subjects: 543
Study 10331686 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA‐chelatable lead
Number of subjects: 543
Study 7813349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral internal anal sphincterotomy
Number of subjects: 40
Study 7813349 — intervention group
Group type: COMPARATOR
Intervention: Anal advancement flap
Number of subjects: 40
Study 1958979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 50
Study 1958979 — intervention group
Group type: COMPARATOR
Intervention: Angelchik prosthesis
Number of subjects: 50
Study 7051729 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study 7051729 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 60
Study 31133052 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural oral hydration volume (quartiles)
Number of subjects: 0
Study 31133052 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration (aggressive or routine)
Number of subjects: 0
Study 30594256 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart phone‐based event recorder (AliveCor Heart Monitor and AliveECG) alongside standard care
Number of subjects: 242
Study 30594256 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 242
Study 26341364 — intervention group
Group type: EXPERIMENTAL
Intervention: TURN score (Thrombolysis risk Using mRS and NIHSS)
Number of subjects: 303
Study 26341364 — intervention group
Group type: EXPERIMENTAL
Intervention: TURN score
Number of subjects: 303
Study 26341364 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour brain swelling
Number of subjects: 303
Study 25456808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG; n = 428) received feedback about children's urine cotinine level (CUCL) and up to two counseling sessions.
Number of subjects: 852
Study 25456808 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n = 424) received a leaflet.
Number of subjects: 852
Study 25456808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG)
Number of subjects: 852
Study 22057473 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Genetic Counseling (GC)
Number of subjects: 65
Study 22057473 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Genetic Counseling (GC)
Number of subjects: 65
Study 20530651 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive therapeutic exercise programme (n=22)
Number of subjects: 42
Study 20530651 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise advice (n=20)
Number of subjects: 42
Study 18696023 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention (40 sessions, 3 times per week) in NHF patients
Number of subjects: 60
Study 18696023 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention in IHF patients
Number of subjects: 60
Study 18696023 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients)
Number of subjects: 60
Study 15649850 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 microg)
Number of subjects: 10
Study 15649850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral slow-release theophylline (Theo-Dur, 600 mg tablets)
Number of subjects: 10
Study 15649850 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of salmeterol and theophylline
Number of subjects: 10
Study 15649850 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (600 mg)
Number of subjects: 10
Study 11960266 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood stem cell (BSC) donation with G-CSF 10 microg/kg s.c., daily for 5 days before leukapheresis
Number of subjects: 61
Study 11960266 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow (BM) donation
Number of subjects: 61
Study 10484534 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) plasma concentrations
Number of subjects: 826
Study 10484534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight apo(a) phenotypes
Number of subjects: 826
Study 8602746 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (6.0 million units, 30 micrograms, administered by intramuscular injection weekly)
Number of subjects: 301
Study 8602746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 8602746 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 301
Study 2011088 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment
Number of subjects: 33
Study 2011088 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with mechanical ventilation alone (Control)
Number of subjects: 33
Study 7156001 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind ribosomal vaccine
Number of subjects: 61
Study 30328708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical noise applied via piezoelectric actuators
Number of subjects: 40
Study 30328708 — intervention group
Group type: COMPARATOR
Intervention: No mechanical noise (control)
Number of subjects: 40
Study 29504585 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact exercise training (6-month multidirectional hopping programme)
Number of subjects: 50
Study 29504585 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 26338433 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity, variable stepping training (70%-80% heart rate reserve), 1-hour sessions, 10 weeks
Number of subjects: 32
Study 26338433 — intervention group
Group type: COMPARATOR
Intervention: Conventional interventions determined by clinical physical therapists
Number of subjects: 32
Study 25268853 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β estradiol (t‐E2) 50 μg/day plus micronized progesterone (m‐P) for 12 days
Number of subjects: 116
Study 25268853 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (o‐CEE) 0.45 mg/day plus micronized progesterone (m‐P) for the first 12 days of the month
Number of subjects: 116
Study 25268853 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills and patch
Number of subjects: 116
Study 22811084 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver catheters
Number of subjects: 325
Study 22811084 — intervention group
Group type: COMPARATOR
Intervention: Plain catheters
Number of subjects: 325
Study 22811084 — intervention group
Group type: EXPERIMENTAL
Intervention: EVD infection
Number of subjects: 325
Study 20819468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 17
Study 20819468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17433901 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 17433901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 0
Study 17433901 — intervention group
Group type: COMPARATOR
Intervention: No treatment or placebo
Number of subjects: 0
Study 15513975 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day
Number of subjects: 30
Study 15513975 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1700 mg/day
Number of subjects: 30
Study 12087449 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus 5-fluorouracil and folinic acid
Number of subjects: 0
Study 12087449 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil and folinic acid
Number of subjects: 0
Study 9869231 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hemoglobin levels (Hgb > or = 14.5 gm% for men, > or = 13 gm% for women)
Number of subjects: 451
Study 9869231 — intervention group
Group type: COMPARATOR
Intervention: Anemic patients (Hgb < 14.5 gm% for men, < 13 gm% for women)
Number of subjects: 451
Study 7808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 0
Study 7808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing with conventional toothpaste
Number of subjects: 0
Study 2698902 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg
Number of subjects: 40
Study 2698902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 4833964 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (single dose)
Number of subjects: 6
Study 4833964 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (repeated doses)
Number of subjects: 6
Study 4833964 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (continuous infusions)
Number of subjects: 6
Study 30139537 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Review (MR)
Number of subjects: 78